Guidant's $135 Mil. InControl Buy Adds Late-Stage Atrial Fibrillation Device
This article was originally published in The Gray Sheet
Executive Summary
Guidant's $135 mil. InControl buy adds the Metrix atrial fibrillation technology to the firm's cardiac rhythm management unit, providing a complement to Guidant's market leading line of ventricular arrhythmia products and a platform for future growth in the $4 bil. worldwide cardiac rhythm management market.